

# LIRAGLUTIDE PLUS CALORIE RESTRICTION PREVENTS THE SPONTANEOUS DEVELOPMENT OF TYPE 1 ENDOMETRIAL CANCER IN BDII/HANS RATS

Nesa Samuel Karunadhas<sup>1</sup>, Ludmilla Dellatorre-Teixeira<sup>1</sup>, Aurelie Fabre<sup>2</sup>, Paul Downey<sup>3</sup>, Anna Isayeva<sup>1</sup>, Donal J Brennan<sup>4</sup>, Carel W le Roux<sup>1</sup> & Neil G Docherty<sup>1</sup>

> <sup>1</sup>UCD Diabetes Complications Research Centre, UCD Conway Institute, University College Dublin, <sup>2</sup> Department of Pathology, St Vincent's University Hospital, Elm Park, Dublin, <sup>3</sup> Department of Pathology, National Maternity Hospital, Holles Street, Dublin, <sup>4</sup> Department of Gynaecological Oncology, UCD School of Medicine, Mater Misericordiae Universtity


#### Introduction

- Glucagon-like 1 peptide (GLP-1) based therapies may hold potential for the prevention and arrest of early-stage Type 1 endometrial cancer (EC1)
- We investigated the impact of the GLP-1 analogue liraglutide in combination with caloric restriction on tumor dynamics in the BDII/Han rat model of spontaneous EC1.


## Methodology

Twelve-month-old BDII/Han rats (n=38) were randomised to either ad libitum access to a standard rodent chow diet (STD n=17) or Liraglutide (1mg/kg/d) therapy plus 50% calorie (LIRdiet n=21). After 3 months, animals were euthanised and uterine horns retrieved to record tumour incidence and assess both tumour type and grade. Oestrus cycle stage was established via assessment of ovarian and endometrial histology.

# Liraglutide daily injections -38 BDII/Han Female Rats Standard Group (n=17) daily injections) (n=21) 10/17 (58.8%) Developed Endometrial cancer by 15 months by 15 months



#### **Endometrium Histology**



High Grade, Dense sclerosing stroma-Invasive

Immune Excluded (X20 H&E stain)



High Grade, Dense sclerosing stroma-Invasive,


Immune Poor(x10 H&E stain)

(x20 C8+)

STD Group Type 1- Endometroid Carcinoma, Low grade Non type 1-Serous Carcinoma, High Grade

(X10 p16+ve)

High Grade, Immune Rich (x20 H&E Stain)




Results


The LIR-diet regimen resulted in 15% weight loss. Tumour incidence was 58% (10 of 17) in STD and 19% (4 of 21) in the LIR group (p = 0.0184). In the STD group, 7 of the 8 tumours assessed histologically were EC1 type, with one animal developing a serous type tumour (EC2). All tumours in the LIRconfirmed EC2 by as group were type, immunohistochemistry and were immune poor/excluded and CD8+ lymphocyte negative. LIR rats were predominantly arrested in diestrus (64%) and proestrus (29.4%), with follicular atresia frequently observed

# Conclusion

- Liraglutide in combination with dietary restriction prevented the development of type 1 endometrial cancer-like disease in BDII/Han rats. Evidence suggests that the treatment also selected for the development of serous type, hormone-independent cancer in a smaller number of animals.
- Calorie restriction complimented with Liraglutide may have suppressed the HPG axis, leading to the downregulation of GNRH, estrogen and ovarian function, resulting in endometrial atrophy giving rise to EC2.


### **Ovarian Histology**








Polymorphonuclear leukocytes (X 10 H&E Stain) Immune Profile Low (X 20 H&E Stain)




\* Metestrus Phase


Corpus Luteum (x10 H&E stain)





Average Ovarian Surface Area mm2 STD **Average Ovarian Surface Area mm2** 

STD Group (x10 H&E stain) LIR Group (x10 H&E stain)









Corpus Luteum (x10 H&E stain)

Corpus Luteum (x10 H&E stain)